ITT - NeuroMetrix reports data from Quell trial for treatment of fibromyalgia; shares up 7%

NeuroMetrix (NURO) perks up 6.6% premarket after announcing top-line results from Quell trial in patients with fibromyalgia. Quell is a novel transcutaneous electrical nerve stimulator ((TENS)) that is indicated for relief and management of chronic pain. A poster titled "Outcome of TENS for Fibromyalgia: Randomized Sham-Controlled Trial" will be presented at the IASP 2021 Congress on Pain June 9-11 & 16-18. Key results include:In the intention-to-treat ((ITT)) population, the treatment difference in the Patient Global Impression of Change (PGIC, primary endpoint) was not significant (sham 3.24 ± 0.26, active 3.58 ± 0.25, p=0.351).However, in subjects with elevated baseline pain sensitivity, the active treatment group exhibited a significant and clinically meaningful improvement compared to sham (sham 3.09±0.40, active 4.24 ± 0.37, p=0.032).Several secondary endpoints were positive in the ITT population. The reduction in the mean FIQR score was significantly greater for active treatment (-14.0 ± 2.1) compared to sham (-6.6 ± 2.2), p=0.001. A

For further details see:

NeuroMetrix reports data from Quell trial for treatment of fibromyalgia; shares up 7%